SCHEMBL4340474

SCHEMBL4340474

CNCCOCCn1c(CCOC)nc2c(N)nc3c(c21)CCCC3

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 19/20 0.35
TLR8 Q9NR97 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335861 0.89 TLR8 (0.42) TLR7TLR8
SCHEMBL5105292 0.88 TLR7 (0.37) TLR7TLR8
SCHEMBL483634 0.83 TLR7 (0.44) TLR7TLR8
SCHEMBL31006028 0.83 TLR7 (0.44) TLR7TLR8
SCHEMBL3872445 0.82 TLR7 (0.39) TLR7TLR8
SCHEMBL5109298 0.82 TLR7 (0.36) TLR7
SCHEMBL3823104 0.81 TLR7 (0.43) TLR7TLR8
SCHEMBL4343043 0.81 TLR7 (0.40) TLR7TLR8
SCHEMBL7102928 0.80 TLR7 (0.43) TLR7
SCHEMBL3971673 0.80 TLR7 (0.44) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612083-B2 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-11-03 US disclosed
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-11 US disclosed
US-7214675-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-08 US disclosed
EP-1341790-B1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2007-02-14 EP disclosed
US-7132429-B2 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-07 US disclosed
US-7115622-B2 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-03 US disclosed
US-7078523-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-18 US disclosed
US-7049439-B2 Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents 3M INNOVATIVE PROPERTIES CO. (US) 2006-05-23 US disclosed
EP-1343784-B1 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. 3M INNOVATIVE PROPERTIES CO (US) 2006-03-08 EP disclosed
US-20050234088-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2005-10-20 US disclosed
US-6660735-B2 Inducing cytokine biosynthesis; viral diseases, neoplastic disorders 3M INNOVATIVE PROPERTIES COMPANY 2003-12-09 US disclosed
US-6656938-B2 Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-12-02 US disclosed
US-20030187016-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
EP-1343784-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M Innovative Properties Company (US) 2003-09-17 EP disclosed
US-20030158192-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2003-08-21 US disclosed
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines UBS AG, STAMFORD BRANCH 2003-07-24 US disclosed
US-20030130518-A1 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. 2003-07-10 US disclosed
US-20030096835-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-19 US disclosed
WO-2002046191-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187016-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR7 14/4885TLR8 51/4885
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES IFNG, IRF3, IL2 TLR7 24/4885TLR8 50/4885
US-20030158192-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR7 84/4885TLR8 273/4885
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 24/4885TLR8 50/4885
US-20050234088-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR7 74/4885TLR8 257/4885
US-20030130518-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR7 84/4885TLR8 273/4885
US-20030096835-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR7 14/4885TLR8 51/4885
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 24/4885TLR8 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.